Navigation Links
TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Date:2/14/2008

o improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by applicable regulatory authorities, or if approved, will prove competitive in the market; and whether the necessary financing to support its drug development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors, such as whether execution of the strategic plan for 2008 will result in maximizing the value of the company's lead compounds, whether the company will identify and enter into a strategic alliance with regard to any of the company's programs, and whether the company's reduction in headcount will have a significant impact on overall expenses of the company. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics annual report on Form 10-K for the year ended Dec. 31, 2006, as well as TorreyPines Therapeutics' subsequent filings with the Securities and Exchange Commission. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Company Contact: Media Contact:

Ev Graham David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x118 212-845-4271

egraham@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact: Investor Contact:

Rhonda Chiger John Baldissera

Rx Communications
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
3. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
4. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
5. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
8. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
9. ImaRx Therapeutics Transitions Business Strategy
10. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Advanced Medical Isotope Corporation ... primarily in the development of brachytherapy devices and ... announced that it has filed a de ... Administration ("FDA") for marketing clearance for its patented ... the U.S. Food, Drug and Cosmetic Act (the ...
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons ... the key link between the medical device industry and ... more in the coming years as the device industry ... According to research by benchmarking firm, Best Practices, ... gain an important edge is by harnessing new technology ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... eTransX recently unveiled the latest version of eTX ... application integration engine. Version 6 delivers on the ... healthcare information systems. The latest version of the ... and enhancements that generate greater efficiencies in creating ...
... Calif., Dec. 17, 2010 SurgiCount Medical, the wholly-owned ... Board: PSTX ) today announced the successful ... Michigan Health System located in Ann Arbor, Michigan.  The ... of the most common surgical errors, retained surgical sponges. ...
Cached Medicine Technology:eTransX Unveils Latest Version of Its eTX HEMI 2SurgiCount Medical Announces the Successful Implementation of the Safety-Sponge® System at the University of Michigan Health System 2SurgiCount Medical Announces the Successful Implementation of the Safety-Sponge® System at the University of Michigan Health System 3
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... risk of burns from fires and cooking accidents increases ... cautious, an expert says. "Between Thanksgiving and New ... coming in with burns," said Dr. Steven Sandoval, medical ... of Stony Brook University Hospital in New York. ... not careful, could quickly turn tragic," Sandoval said in ...
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... 2014 AngelWeddingDress.com tries its best to ... realm. Today, the business has introduced its new collection ... dress promotion. , The new prom outfits are guaranteed ... dress lover. They are specially designed for 2015. Anyone ... dresses should visit its website before Jan. 26, 2015, ...
(Date:12/25/2014)... December 25, 2014 “ SmileStix ” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review and shared ... create personal stickers. , The old saying goes, “A picture ... of words that can describe a single image, because each ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... to be remotely monitored through XTend,s Disease ... ... (Pink Sheets: XMDC) announced today the company has begun a,remote diabetic ... the initial program., The program, facilitated through local physicians in ...
... has shown that the main metabolite of the insecticide ... but there has been no explanation for this observation ... access journal Breast Cancer Research shows how DDT could ... Aube and colleagues from Universite Laval and Institut national ...
... LANDOVER, Md., Feb. 13 Valentine,s Day is,not just ... saint of,lovers, St. Valentine, takes on greater meaning when ... -- a common neurological condition that,causes seizures, and affects ... States, according to the Epilepsy Foundation., Some accounts ...
... Feb. 13 ReBuilder Medical,Technologies, Inc. (Pink ... art,electronic devices for diabetic peripheral neuropathy, Molluscum,Contagiosum, ... over last year, details,are available on their ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ), "The ...
... SEGUNDO, Calif., Feb. 13 DaVita Inc.,(NYSE: DVA ... ended December,31, 2007. Net income for the three months ... share, as compared to $74.1 million, or $0.70 per,share, ... http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ), Net income for the year ended ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... informatics products, announced today,that it will present at ... Conference on Wednesday, February 20, 2008 at the ... vice president and chief,financial officer, will present the ...
Cached Medicine News:Health News:XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program 2Health News:How DDT metabolite disrupts breast cancer cells 2Health News:ReBuilder Medical Technologies, Inc. Announces 2007 Sales Nearly Doubled Sales in 2006 2Health News:DaVita 4th Quarter 2007 Results 2Health News:DaVita 4th Quarter 2007 Results 3Health News:DaVita 4th Quarter 2007 Results 4Health News:DaVita 4th Quarter 2007 Results 5Health News:DaVita 4th Quarter 2007 Results 6Health News:DaVita 4th Quarter 2007 Results 7Health News:DaVita 4th Quarter 2007 Results 8Health News:DaVita 4th Quarter 2007 Results 9Health News:DaVita 4th Quarter 2007 Results 10Health News:DaVita 4th Quarter 2007 Results 11Health News:DaVita 4th Quarter 2007 Results 12Health News:DaVita 4th Quarter 2007 Results 13Health News:DaVita 4th Quarter 2007 Results 14Health News:DaVita 4th Quarter 2007 Results 15Health News:DaVita 4th Quarter 2007 Results 16Health News:DaVita 4th Quarter 2007 Results 17Health News:Cardiac Science to Present at the Roth Capital Partners 20th Annual Growth Stock Conference 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: